EnTrust Global Completes Acquisition of Maas Capital From ABN AMRO
The Blue Ocean strategy managed by EnTrust Global (“EnTrust”), a leading alternative asset management firm, announced today that it has completed the acquisition of Maas Capital Shipping B.V. from ABN AMRO. Since its inception in the late 1990s, the Maas Capital platform has deployed close to $1.0 billion in equity maritime investments and is currently one of the world’s leading institutional shipping equity investors. The acquired portfolio includes a diversified portfolio of 15 equity joint venture investments, consisting of a fleet of 76 high-quality vessels within the product/chemical tanker, dry bulk, LPG, container, and offshore services segments. In addition, the portfolio includes an equity stake in a growing intermodal business which leases out container boxes. The acquisition is the latest expansion of EnTrust’s maritime finance strategy, Blue Ocean, which is part of the firm’s broader maritime-focused Blue Ocean Group.
As part of the transaction, EnTrust has engaged six members of the Maas Capital team led by Mark Ras, who will continue to be involved with the management of the portfolio and to source additional growth opportunities for EnTrust.
“The completion of the Maas Capital portfolio acquisition is another step in our expansion into the equity investment space, and something we view as a significant asset for the Blue Ocean strategy,” said Svein Engh, Senior Managing Director of EnTrust Global and Portfolio Manager of Blue Ocean Group. “We look forward to partnering with the Maas Capital team and its extensive experience and to continue the momentum generated by the portfolio in recent years, all at a time when fundamentals continue to stabilize in the global maritime industry.”
"This acquisition allows the Blue Ocean strategy to continue the growth of its maritime investment portfolio as a leading alternative capital provider to the shipping sector. We are excited to team up with shipping companies that we view as best-in-class partners and look forward to establishing new partnerships with other leaders in the space,” said Omer Donnerstein, Managing Director of EnTrust Global and Investment Analyst for Blue Ocean.
“We are extremely pleased to partner with EnTrust and look forward to continuing to manage and expand the business. This marks a new and exciting chapter in the development of Maas Capital as we expand existing investments, bring on new partners and venture into new markets. A special thanks also goes out to our existing partners, team and stakeholders for their patience and support in this process,” said Mark Ras, Head of Maas Capital.
Since its inception the Blue Ocean strategy has raised $2.6 billion.
EnTrust was represented by Watson Farley & Williams (London) and NautaDutilh (Amsterdam).
About EnTrust Global
EnTrust Global is a leading alternative asset management firm with approximately $19.7 billion in total assets.* Co-founded in 1997 by Chairman and CEO Gregg S. Hymowitz, the firm manages assets for over 500 institutional investors representing 48 countries and has approximately $11 billion in customized strategic partnerships. EnTrust Global offers a diverse range of alternative investment opportunities across strategies, including private debt and real assets as well as opportunistic co-investments and direct investments. EnTrust Global has 10 offices worldwide and is headquartered in New York and London.
*As of June 30, 2021. Based on estimates and includes assets under advisement and mandates awarded but not yet funded.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005268/en/
Contact information
Media:
EnTrust Global
Hiltzik Strategies
Meghan Kilkenny
EnTrust@hstrategies.com
+1 (212) 792-9338
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO8.1.2026 11:03:00 EET | Press release
Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/ Daniel Cohen, CEO Alpega Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 10:00:00 EET | Press release
Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 09:00:00 EET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 08:30:00 EET | Press release
4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). The U.S. Food and Drug Administration (FDA) approval marks another strategic step in 4MB’s global clinical deployment across
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo ® in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 08:30:00 EET | Press release
Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnier Leconte, AVP & Managing Director at Organon Northwest Europe. “By offering a new treatment option for patients who cannot tolerate statins, we are helping to close a persistent gap in cardiovascular care—one that disproportionately affects women – whilst reinforcing our mission to deliver impactful treatments for a healthier every day.” Cardiovascular disease i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom